- Trials with a EudraCT protocol (205)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
205 result(s) found for: Drug Court.
Displaying page 1 of 11.
EudraCT Number: 2015-001588-37 | Sponsor Protocol Number: ACHN-490-009 | Start Date*: 2015-07-15 | |||||||||||
Sponsor Name:Achaogen, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared with Meropenem followed by Optional Oral Therapy for the Treatment of Complicated U... | |||||||||||||
Medical condition: Complicated Urinary Tract Infection (cUTI) Acute Pyelonephritis (AP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Completed) DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001890-15 | Sponsor Protocol Number: SD-809-C-18 | Start Date*: 2014-11-12 |
Sponsor Name:Auspex Pharmaceuticals, Inc. | ||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA | ||
Medical condition: Tardive Dyskinesia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) PL (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004740-36 | Sponsor Protocol Number: PTCEMF-GD-004 | Start Date*: 2019-10-14 | |||||||||||
Sponsor Name:PTC Therapeutics, Inc. | |||||||||||||
Full Title: A MULTICENTER RANDOMIZED PLACEBO-CONTROLLED PHASE 3 STUDY ON THE SAFETY AND EFFICACY OF DEFLAZACORT (EMFLAZA®) IN SUBJECTS WITH LIMB-GIRDLE MUSCULAR DYSTROPHY 2I (LGMD2I | |||||||||||||
Medical condition: Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001764-11 | Sponsor Protocol Number: PTC124-GD-030-DMD | Start Date*: 2020-01-21 | ||||||||||||||||
Sponsor Name:PTC Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy | ||||||||||||||||||
Medical condition: nonsense mutation dystrophinopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-005153-37 | Sponsor Protocol Number: LJ501-CRH04 | Start Date*: 2018-07-11 |
Sponsor Name:La Jolla Pharmaceutical Company | ||
Full Title: A Randomised, Placebo-controlled, Double-blind, Multicentre Efficacy and Safety Study of LJPC-501 in Paediatric Patients > 2 to 17 Years of Age with Catecholamine-Resistant Hypotension Associated w... | ||
Medical condition: Catecholamine-resistant hypotension associated with distributive shock | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Ongoing) EE (Completed) LT (Prematurely Ended) FR (Ongoing) ES (Temporarily Halted) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000331-27 | Sponsor Protocol Number: ANB020-005 | Start Date*: 2018-09-18 | |||||||||||
Sponsor Name:AnaptysBio Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects with Mode... | |||||||||||||
Medical condition: Moderate-to-Severe Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002562-42 | Sponsor Protocol Number: TRCA-301E | Start Date*: 2017-12-15 | |||||||||||
Sponsor Name:Tricida, Inc. | |||||||||||||
Full Title: A Blinded, Placebo-Controlled Extension to Study TRCA-301 to Evaluate the Long-term Safety and Durability of Effect of TRC101 in Subjects with Chronic Kidney Disease and Metabolic Acidosis | |||||||||||||
Medical condition: Metabolic acidosis associated with Chronic Kidney Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) HU (Completed) SI (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000060-16 | Sponsor Protocol Number: AMIK-04-02 | Start Date*: 2005-05-06 |
Sponsor Name:Aerogen, Inc. | ||
Full Title: A Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Dose-Ranging Study of Nebulized Amikacin Delivered Via the Pulmonary Drug Delivery System (PDDS) in Patients With Ventilator-Associated Pn... | ||
Medical condition: Ventilator associated pneumonia (VAP) caused by gram negative organisms. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002939-15 | Sponsor Protocol Number: V56502 | Start Date*: 2017-01-24 | |||||||||||
Sponsor Name:VHsquared Ltd | |||||||||||||
Full Title: A Phase 2 study to investigate the efficacy, safety, and tolerability of six weeks treatment with V565 in subjects with active Crohn’s disease. | |||||||||||||
Medical condition: Active Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) AT (Completed) HU (Completed) SK (Completed) NL (Completed) NO (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003135-19 | Sponsor Protocol Number: SD-809-C-23 | Start Date*: 2015-02-06 |
Sponsor Name:Auspex Pharmaceuticals, Inc. | ||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA | ||
Medical condition: Tardive Dyskinesia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) PL (Completed) CZ (Completed) HU (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000375-39 | Sponsor Protocol Number: PTC743-CNS-005-LSEP | Start Date*: 2022-12-07 | |||||||||||
Sponsor Name:PTC THERAPEUTICS INC. | |||||||||||||
Full Title: AN OPEN-LABEL, SAFETY STUDY FOR PREVIOUSLY TREATED VATIQUINONE (PTC743) SUBJECTS WITH INHERITED MITOCHONDRIAL DISEASE | |||||||||||||
Medical condition: Inherited mitochondrial disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) FR (Ongoing) SE (Completed) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002100-39 | Sponsor Protocol Number: PTC743-MIT-001-EP | Start Date*: 2021-07-26 | ||||||||||||||||
Sponsor Name:PTC THERAPEUTICS, INC. | ||||||||||||||||||
Full Title: Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy (MIT-E) | ||||||||||||||||||
Medical condition: Genetically determined mitochondrial disease and associated refractory epilepsy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Temporarily Halted) FR (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) PL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001303-36 | Sponsor Protocol Number: TRCA-303 | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:Tricida Inc. | |||||||||||||
Full Title: A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis | |||||||||||||
Medical condition: Chronic kidney disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Ongoing) SK (Completed) CZ (Completed) BE (Completed) ES (Prematurely Ended) PT (Completed) NL (Prematurely Ended) PL (Completed) IT (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005019-16 | Sponsor Protocol Number: ROCKSAN | Start Date*: 2009-03-19 |
Sponsor Name:AMC- academisch psychiatrisch centrum | ||
Full Title: Randomized Olanzapine Clozapine Key study on Schizophrenia and Addiction in the Netherlands (ROCKSAN) | ||
Medical condition: A multi-centre prospective, randomized, double blind designed study examining the effectiveness and costs of clozapine compared to olanzapine in patients with schizophrenia or related psychotic dis... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000360-42 | Sponsor Protocol Number: UX001-CL302 | Start Date*: 2016-08-02 | ||||||||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc. | ||||||||||||||||||
Full Title: A Phase 3b Open-label Extension Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients with GNE Myopathy (GNEM) or Hereditary Inclusion Body Myo... | ||||||||||||||||||
Medical condition: GNE Myopathy, also known as Hereditary Inclusion Body Myopathy (HIBM), Distal Myopathy with Rimmed Vacuoles (DMRV), Nonaka's disease, or quadriceps sparing myopathy (QSM) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-002192-19 | Sponsor Protocol Number: ISIS678354-CS5 | Start Date*: 2022-07-22 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia | ||||||||||||||||||
Medical condition: Severe hypertryglyceridemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Ongoing) NO (Ongoing) ES (Ongoing) HU (Ongoing) NL (Ongoing) CZ (Ongoing) FI (Ongoing) BG (Ongoing) SK (Ongoing) PT (Ongoing) PL (Ongoing) DK (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001875-32 | Sponsor Protocol Number: UX003-CL202 | Start Date*: 2015-11-12 |
Sponsor Name:Ultragenyx Pharmaceutical Inc. | ||
Full Title: A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects with MPS 7 | ||
Medical condition: Mucopolysaccharidosis type 7 (MPS 7, Sly syndrome) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-000389-69 | Sponsor Protocol Number: UX007G-CL202 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc | |||||||||||||
Full Title: An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome | |||||||||||||
Medical condition: Glucose Transporter Type 1 deficiency syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002165-21 | Sponsor Protocol Number: ISIS416858-CS5 | Start Date*: 2017-11-23 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals Inc. | ||||||||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ISIS 416858 (IONIS-FXIRX an Antisense Inhibitor of Factor XI... | ||||||||||||||||||
Medical condition: Prevention of thrombosis while on hemodialysis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) CZ (Completed) AT (Completed) NL (Completed) BG (Completed) BE (Completed) GR (Completed) LV (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-005115-13 | Sponsor Protocol Number: ISIS420915-CS4 | Start Date*: 2018-04-25 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Non-Interventional Study to Monitor the Survival Status of Patients that Discontinued from ISIS 420915-CS2 or ISIS 420915-CS3 | |||||||||||||
Medical condition: Familial Amyloid Polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Ongoing) GB (Completed) PT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.